127 related articles for article (PubMed ID: 20682657)
1. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Albanese C; Alzani R; Amboldi N; Avanzi N; Ballinari D; Brasca MG; Festuccia C; Fiorentini F; Locatelli G; Pastori W; Patton V; Roletto F; Colotta F; Galvani A; Isacchi A; Moll J; Pesenti E; Mercurio C; Ciomei M
Mol Cancer Ther; 2010 Aug; 9(8):2243-54. PubMed ID: 20682657
[TBL] [Abstract][Full Text] [Related]
2. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
4. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
[TBL] [Abstract][Full Text] [Related]
6. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
7. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
[TBL] [Abstract][Full Text] [Related]
8. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
[TBL] [Abstract][Full Text] [Related]
9. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
10. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
11. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Byth KF; Thomas A; Hughes G; Forder C; McGregor A; Geh C; Oakes S; Green C; Walker M; Newcombe N; Green S; Growcott J; Barker A; Wilkinson RW
Mol Cancer Ther; 2009 Jul; 8(7):1856-66. PubMed ID: 19509270
[TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
[TBL] [Abstract][Full Text] [Related]
13. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
14. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Weiss GJ; Hidalgo M; Borad MJ; Laheru D; Tibes R; Ramanathan RK; Blaydorn L; Jameson G; Jimeno A; Isaacs JD; Scaburri A; Pacciarini MA; Fiorentini F; Ciomei M; Von Hoff DD
Invest New Drugs; 2012 Dec; 30(6):2334-43. PubMed ID: 22160853
[TBL] [Abstract][Full Text] [Related]
16. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
Hirai H; Takahashi-Suziki I; Shimomura T; Fukasawa K; Machida T; Takaki T; Kobayashi M; Eguchi T; Oki H; Arai T; Ichikawa K; Hasako S; Kodera T; Kawanishi N; Nakatsuru Y; Kotani H; Iwasawa Y
Invest New Drugs; 2011 Aug; 29(4):534-43. PubMed ID: 20084424
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.
Zhang C; Lundgren K; Yan Z; Arango ME; Price S; Huber A; Higgins J; Troche G; Skaptason J; Koudriakova T; Nonomiya J; Yang M; O'Connor P; Bender S; Los G; Lewis C; Jessen B
Mol Cancer Ther; 2008 Apr; 7(4):818-28. PubMed ID: 18413795
[TBL] [Abstract][Full Text] [Related]
18. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.
Locatelli G; Bosotti R; Ciomei M; Brasca MG; Calogero R; Mercurio C; Fiorentini F; Bertolotti M; Scacheri E; Scaburri A; Galvani A; Pesenti E; De Baere T; Soria JC; Lazar V; Isacchi A
Mol Cancer Ther; 2010 May; 9(5):1265-73. PubMed ID: 20423997
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Alzani R; Pedrini O; Albanese C; Ceruti R; Casolaro A; Patton V; Colotta F; Rambaldi A; Introna M; Pesenti E; Ciomei M; Golay J
Exp Hematol; 2010 Apr; 38(4):259-269.e2. PubMed ID: 20167248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
